Skip to content

OncoMed Pharmaceuticals Inc

Delisted

CIK 1302573fmd_1CR9A5ZB5HXE0G26H2W4XYRYREManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2011 to Dec 31, 2018, 29 periods

Latest annual · FY2018

Millions
Total revenues
44
Operating income
(10)
Net income
(8)
Free cash flow
(46)

Latest quarter · Q4 FY2018

Millions
Total revenues
10
Operating income
(5)
Net income
(5)
Free cash flow
(14)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2015 to FY2018
+19.7%
Revenue, 5 yearsFY2013 to FY2018
+3.3%
Net income, 5 yearsFY2013 to FY2018
n/m

OncoMed Pharmaceuticals Inc financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2018FY2017ChangeSource
Revenue$44.4 million$38.2 million+16.4%10-K 2019-03-07 · proof
Operating income-$10 million-$41 million10-K 2019-03-07 · proof
Net income-$8.1 million-$39.1 million10-K 2019-03-07 · proof
Cash from operating activities-$44.9 million-$85 million10-K 2019-03-07 · proof
Free cash flow-$45.5 million-$85.6 million10-K 2019-03-07 · proof
Total assets$65.1 million$110.3 million-41%10-K 2019-03-07 · proof
Total liabilities$16.8 million$158.9 million-89.4%10-K 2019-03-07 · proof
Cash and cash equivalents$9.7 million$13.3 million-27%10-K 2019-03-07 · proof
What was OncoMed Pharmaceuticals Inc's revenue in fiscal 2018?
OncoMed Pharmaceuticals Inc reported revenue of $44.4 million for fiscal 2018 (the year ended Dec 31, 2018), against $38.2 million the year before (+16.4%). Source: the 10-K filed with the SEC on Mar 7, 2019. SEC
What was OncoMed Pharmaceuticals Inc's operating income in fiscal 2018?
OncoMed Pharmaceuticals Inc reported operating income of -$10 million for fiscal 2018 (the year ended Dec 31, 2018), against -$41 million the year before. Source: the 10-K filed with the SEC on Mar 7, 2019. SEC
What was OncoMed Pharmaceuticals Inc's net income in fiscal 2018?
OncoMed Pharmaceuticals Inc reported net income of -$8.1 million for fiscal 2018 (the year ended Dec 31, 2018), against -$39.1 million the year before. Source: the 10-K filed with the SEC on Mar 7, 2019. SEC
What was OncoMed Pharmaceuticals Inc's cash from operating activities in fiscal 2018?
OncoMed Pharmaceuticals Inc reported cash from operating activities of -$44.9 million for fiscal 2018 (the year ended Dec 31, 2018), against -$85 million the year before. Source: the 10-K filed with the SEC on Mar 7, 2019. SEC
What was OncoMed Pharmaceuticals Inc's free cash flow in fiscal 2018?
OncoMed Pharmaceuticals Inc reported free cash flow of -$45.5 million for fiscal 2018 (the year ended Dec 31, 2018), against -$85.6 million the year before. Source: the 10-K filed with the SEC on Mar 7, 2019. SEC
What are OncoMed Pharmaceuticals Inc's total assets?
As of Dec 31, 2018, OncoMed Pharmaceuticals Inc reported total assets of $65.1 million, against $110.3 million a year earlier (-41%). Source: the 10-K filed with the SEC on Mar 7, 2019. SEC
What are OncoMed Pharmaceuticals Inc's total liabilities?
As of Dec 31, 2018, OncoMed Pharmaceuticals Inc reported total liabilities of $16.8 million, against $158.9 million a year earlier (-89.4%). Source: the 10-K filed with the SEC on Mar 7, 2019. SEC
What are OncoMed Pharmaceuticals Inc's cash and cash equivalents?
As of Dec 31, 2018, OncoMed Pharmaceuticals Inc reported cash and cash equivalents of $9.7 million, against $13.3 million a year earlier (-27%). Source: the 10-K filed with the SEC on Mar 7, 2019. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1302573&period_type=annual&limit=5"

Information only, not investment advice.